Patrick P. Grace Sells 284 Shares of Chemed Co. (NYSE:CHE) Stock

Chemed Co. (NYSE:CHE) Director Patrick P. Grace sold 284 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $540.98, for a total value of $153,638.32. Following the sale, the director now directly owns 3,270 shares in the company, valued at approximately $1,769,004.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Chemed Stock Up 0.0 %

Shares of NYSE CHE opened at $538.45 on Friday. The stock has a market cap of $8.15 billion, a PE ratio of 28.98, a price-to-earnings-growth ratio of 2.23 and a beta of 0.46. Chemed Co. has a 52-week low of $492.84 and a 52-week high of $654.62. The business has a 50-day moving average price of $572.23 and a 200 day moving average price of $591.29.

Chemed (NYSE:CHE) last posted its quarterly earnings data on Wednesday, April 24th. The company reported $4.68 earnings per share for the quarter, missing the consensus estimate of $5.09 by ($0.41). The firm had revenue of $589.23 million during the quarter, compared to analyst estimates of $587.18 million. Chemed had a net margin of 12.36% and a return on equity of 30.52%. Sell-side analysts anticipate that Chemed Co. will post 21.54 earnings per share for the current year.

Chemed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 18th. Shareholders of record on Thursday, May 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, May 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.30%. Chemed’s dividend payout ratio is presently 8.61%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CHE. StockNews.com upgraded shares of Chemed from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. Oppenheimer increased their target price on shares of Chemed from $625.00 to $650.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Finally, Royal Bank of Canada reduced their price target on shares of Chemed from $712.00 to $697.00 and set an “outperform” rating for the company in a research report on Tuesday, May 21st.

Institutional Investors Weigh In On Chemed

Institutional investors and hedge funds have recently made changes to their positions in the business. Rise Advisors LLC acquired a new position in Chemed in the 1st quarter valued at about $26,000. GAMMA Investing LLC purchased a new stake in shares of Chemed during the fourth quarter worth approximately $37,000. Principal Securities Inc. acquired a new stake in shares of Chemed during the fourth quarter worth $51,000. SRS Capital Advisors Inc. grew its position in Chemed by 110.6% in the 4th quarter. SRS Capital Advisors Inc. now owns 99 shares of the company’s stock valued at $58,000 after buying an additional 52 shares during the last quarter. Finally, Mather Group LLC. acquired a new position in Chemed in the 1st quarter valued at $67,000. 95.85% of the stock is owned by hedge funds and other institutional investors.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.